Boston, MA, based Investment company Cormorant Asset Management, LLC (Current Portfolio) buys Acceleron Pharma Inc, Agenus Inc, Eidos Therapeutics Inc, Cabaletta Bio Inc, Omeros Corp, sells Reata Pharmaceuticals Inc, Mirati Therapeutics Inc, ChemoCentryx Inc, CRISPR Therapeutics AG, Ascendis Pharma A/S during the 3-months ended 2020Q1, according to the most recent filings of the investment company, Cormorant Asset Management, LLC. As of 2020Q1, Cormorant Asset Management, LLC owns 66 stocks with a total value of $2 billion. These are the details of the buys and sells.

For the details of Cormorant Asset Management, LLC's stock buys and sells,
go to www.gurufocus.com/guru/cormorant+asset+management%2C+llc/current-portfolio/portfolio

These are the top 5 holdings of Cormorant Asset Management, LLC

  1. SPDR S&P 500 (SPY) - 1,000,000 shares, 12.82% of the total portfolio.
  2. Turning Point Therapeutics Inc (TPTX) - 3,056,797 shares, 6.79% of the total portfolio. Shares reduced by 10.01%
  3. Principia Biopharma Inc (PRNB) - 2,100,000 shares, 6.20% of the total portfolio. Shares added by 5.48%
  4. BridgeBio Pharma Inc (BBIO) - 2,950,000 shares, 4.25% of the total portfolio. Shares added by 17.40%
  5. ChemoCentryx Inc (CCXI) - 2,025,000 shares, 4.05% of the total portfolio. Shares reduced by 30.17%

New Purchase: Acceleron Pharma Inc (XLRN)

Cormorant Asset Management, LLC initiated holding in Acceleron Pharma Inc. The purchase prices were between $50.95 and $95.31, with an estimated average price of $77.26. The stock is now traded at around $99.37. The impact to a portfolio due to this purchase was 3.69%. The holding were 825,000 shares as of .

New Purchase: Agenus Inc (AGEN)

Cormorant Asset Management, LLC initiated holding in Agenus Inc. The purchase prices were between $1.92 and $4.39, with an estimated average price of $3.23. The stock is now traded at around $3.73. The impact to a portfolio due to this purchase was 1.48%. The holding were 12,174,486 shares as of .

New Purchase: Cabaletta Bio Inc (CABA)

Cormorant Asset Management, LLC initiated holding in Cabaletta Bio Inc. The purchase prices were between $6 and $18.67, with an estimated average price of $13.79. The stock is now traded at around $7.31. The impact to a portfolio due to this purchase was 0.76%. The holding were 2,105,846 shares as of .

New Purchase: Homology Medicines Inc (FIXX)

Cormorant Asset Management, LLC initiated holding in Homology Medicines Inc. The purchase prices were between $12.5 and $22.04, with an estimated average price of $17.1. The stock is now traded at around $15.78. The impact to a portfolio due to this purchase was 0.46%. The holding were 600,000 shares as of .

New Purchase: Insmed Inc (INSM)

Cormorant Asset Management, LLC initiated holding in Insmed Inc. The purchase prices were between $13.63 and $33.98, with an estimated average price of $23.78. The stock is now traded at around $28.42. The impact to a portfolio due to this purchase was 0.29%. The holding were 362,273 shares as of .

New Purchase: Arcturus Therapeutics Holdings Inc (ARCT)

Cormorant Asset Management, LLC initiated holding in Arcturus Therapeutics Holdings Inc. The purchase prices were between $9.31 and $18.26, with an estimated average price of $12.77. The stock is now traded at around $40.06. The impact to a portfolio due to this purchase was 0.18%. The holding were 262,037 shares as of .

Added: Eidos Therapeutics Inc (EIDX)

Cormorant Asset Management, LLC added to a holding in Eidos Therapeutics Inc by 121.91%. The purchase prices were between $38.03 and $58.69, with an estimated average price of $51.13. The stock is now traded at around $49.46. The impact to a portfolio due to this purchase was 1.47%. The holding were 1,100,000 shares as of .

Added: Omeros Corp (OMER)

Cormorant Asset Management, LLC added to a holding in Omeros Corp by 65.49%. The purchase prices were between $9.03 and $19.72, with an estimated average price of $13.32. The stock is now traded at around $15.04. The impact to a portfolio due to this purchase was 0.66%. The holding were 2,523,700 shares as of .

Added: AnaptysBio Inc (ANAB)

Cormorant Asset Management, LLC added to a holding in AnaptysBio Inc by 203.53%. The purchase prices were between $12.82 and $18.69, with an estimated average price of $15.2. The stock is now traded at around $19.25. The impact to a portfolio due to this purchase was 0.52%. The holding were 1,107,900 shares as of .

Added: Blueprint Medicines Corp (BPMC)

Cormorant Asset Management, LLC added to a holding in Blueprint Medicines Corp by 30.43%. The purchase prices were between $48.11 and $82.22, with an estimated average price of $64.89. The stock is now traded at around $76.32. The impact to a portfolio due to this purchase was 0.31%. The holding were 450,000 shares as of .

Added: Myovant Sciences Ltd (MYOV)

Cormorant Asset Management, LLC added to a holding in Myovant Sciences Ltd by 30.00%. The purchase prices were between $6.55 and $15.52, with an estimated average price of $11.33. The stock is now traded at around $16.70. The impact to a portfolio due to this purchase was 0.23%. The holding were 2,600,000 shares as of .

Added: Sorrento Therapeutics Inc (SRNE)

Cormorant Asset Management, LLC added to a holding in Sorrento Therapeutics Inc by 25.00%. The purchase prices were between $1.57 and $4.76, with an estimated average price of $2.91. The stock is now traded at around $4.80. The impact to a portfolio due to this purchase was 0.09%. The holding were 5,000,000 shares as of .

Sold Out: Ra Pharmaceuticals Inc (RARX)

Cormorant Asset Management, LLC sold out a holding in Ra Pharmaceuticals Inc. The sale prices were between $40.51 and $48.01, with an estimated average price of $46.53.

Reduced: Reata Pharmaceuticals Inc (RETA)

Cormorant Asset Management, LLC reduced to a holding in Reata Pharmaceuticals Inc by 40.32%. The sale prices were between $124.16 and $247.74, with an estimated average price of $194.02. The stock is now traded at around $160.45. The impact to a portfolio due to this sale was -2.78%. Cormorant Asset Management, LLC still held 487,206 shares as of .

Reduced: Mirati Therapeutics Inc (MRTX)

Cormorant Asset Management, LLC reduced to a holding in Mirati Therapeutics Inc by 33.72%. The sale prices were between $69.78 and $128.86, with an estimated average price of $90.44. The stock is now traded at around $108.86. The impact to a portfolio due to this sale was -2.3%. Cormorant Asset Management, LLC still held 850,000 shares as of .

Reduced: ChemoCentryx Inc (CCXI)

Cormorant Asset Management, LLC reduced to a holding in ChemoCentryx Inc by 30.17%. The sale prices were between $32.73 and $50.78, with an estimated average price of $42.52. The stock is now traded at around $60.28. The impact to a portfolio due to this sale was -1.43%. Cormorant Asset Management, LLC still held 2,025,000 shares as of .

Reduced: CRISPR Therapeutics AG (CRSP)

Cormorant Asset Management, LLC reduced to a holding in CRISPR Therapeutics AG by 36.96%. The sale prices were between $33.68 and $62.53, with an estimated average price of $51.94. The stock is now traded at around $67.34. The impact to a portfolio due to this sale was -0.93%. Cormorant Asset Management, LLC still held 630,400 shares as of .

Here is the complete portfolio of Cormorant Asset Management, LLC. Also check out:

1. Cormorant Asset Management, LLC's Undervalued Stocks
2. Cormorant Asset Management, LLC's Top Growth Companies, and
3. Cormorant Asset Management, LLC's High Yield stocks
4. Stocks that Cormorant Asset Management, LLC keeps buying



Source link